Xanthine oxidoreductase activity in platelet-poor and rich plasma as a oxidative stress indicator in patients required renal replacement therapy

Table 9 Analysis of the influence of the tested parameters on the XOR isoforms activity - multivariate regression analysis

Dependent variable	Independent varaible	β	R²	p	P for model	F
XO in PPP	Type of renal replacement therapy	-0,59	0,33	0,8	0,004	2,46
	Age	-0,90	0,33	0,89	0,004	2,46
	Duration of dialysis	−14,20		0,54
	Stage of CKD	0,028		0,85
	CKD causes	−4,25		0,74
XD in PRP	Type of renal replacement therapy	−1,95	0,39	0,38	<0,001	3,22
	age	−3,83	0,39	0,54	<0,001	3,22
	Duration of dialysis	−25,10		0,25
	Stage of CKD	−8,35		0,49
	CKD causes	−0,16		0,28
XO in PRP	Type of renal replacement therapy	−4,48	0,32	0,08	0,006	2,37
	age	−13,20	0,32	0,07	0,006	2,37
	Duration of dialysis	−26,21		0,3
	Stage of CKD	0,16		0,09
	CKD causes	−24,12		0,09

β - standardized coefficient in the regression equation, R2 - coefficient of determination, p - value of the significance coefficient; XO in PPP-oxidase isoform in platelet poor plasma, XD in PRP - dehydrogenase isoform in platelet-rich plasma, XO in PRP- oxidase isoform in plasma

ISSN: 1471-2369